| Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? MP Ward, L E Kane, L A Norris, BM Mohamed, T Kelly, M Bates, A Clarke, ... Molecular cancer 20, 1-17, 2021 | 83 | 2021 |
| The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer CJ d'Adhemar, CD Spillane, MF Gallagher, M Bates, KM Costello, ... PLoS One 9 (6), e100816, 2014 | 54 | 2014 |
| Triage of LSIL/ASC‐US with p16/Ki‐67 dual staining and human papillomavirus testing: a 2‐year prospective study C White, S Bakhiet, M Bates, H Keegan, L Pilkington, C Ruttle, L Sharp, ... Cytopathology 27 (4), 269-276, 2016 | 47 | 2016 |
| FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer S Annett, G Moore, A Short, A Marshall, C McCrudden, A Yakkundi, S Das, ... British Journal of Cancer 122 (3), 361-371, 2020 | 44 | 2020 |
| Too MAD or not MAD enough: The duplicitous role of the spindle assembly checkpoint protein MAD2 in cancer M Bates, F Furlong, MF Gallagher, CD Spillane, A McCann, S O'Toole, ... Cancer Letters 469, 11-21, 2020 | 21 | 2020 |
| CD10−/ALDH− cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy B Ffrench, C Gasch, K Hokamp, C Spillane, G Blackshields, TM Mahgoub, ... Cell Death & Disease 8 (10), e3128-e3128, 2017 | 16 | 2017 |
| YB-1: The key to personalised prostate cancer management? M Bates, A Boland, N McDermott, L Marignol Cancer letters 490, 66-75, 2020 | 15 | 2020 |
| Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer C Martini, JM Logan, A Sorvina, C Gordon, AR Beck, BSY Ung, ... Pathology 55 (1), 40-51, 2023 | 13 | 2023 |
| Prognostic features of the tumour microenvironment in oesophageal adenocarcinoma R McShane, S Arya, AJ Stewart, PD Caie, M Bates Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1876 (2), 188598, 2021 | 10 | 2021 |
| The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer M Bates, CD Spillane, MF Gallagher, A McCann, C Martin, G Blackshields, ... PloS one 15 (12), e0243715, 2020 | 10 | 2020 |
| Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance S Inder, M Bates, N Ni Labhrai, N McDermott, J Schneider, G Erdmann, ... Scientific Reports 9 (1), 17325, 2019 | 10 | 2019 |
| Exposure to tobacco smoke measured by urinary nicotine metabolites increases risk of p16/Ki-67 co-expression and high-grade cervical neoplasia in HPV positive women: A two year … CM White, S Bakhiet, M Bates, C Ruttle, LJ Pilkington, H Keegan, ... Cancer epidemiology 68, 101793, 2020 | 9 | 2020 |
| MyD88 is an essential component of retinoic acid-induced differentiation in human pluripotent embryonal carcinoma cells G Sulaiman, A Cooke, B Ffrench, C Gasch, OA Abdullai, K O’Connor, ... Cell Death & Differentiation 24 (11), 1975-1986, 2017 | 8 | 2017 |
| Prediction of prostate cancer biochemical and clinical recurrence is improved by IHC-assisted grading using Appl1, Sortilin and Syndecan-1 JM Logan, AM Hopkins, C Martini, A Sorvina, P Tewari, S Prabhakaran, ... Cancers 15 (12), 3215, 2023 | 7 | 2023 |
| Circulating tumour cells: The Good, the Bad and the Ugly M Bates, BM Mohamed, MP Ward, TE Kelly, R O’Connor, V Malone, ... Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1878 (2), 188863, 2023 | 7 | 2023 |
| The induction of a mesenchymal phenotype by platelet cloaking of cancer cells is a universal phenomenon CD Spillane, NM Cooke, MP Ward, D Kenny, G Blackshields, T Kelly, ... Translational Oncology 14 (12), 101229, 2021 | 7 | 2021 |
| Ex vivo expansion of circulating tumour cells (CTCs) BM Mohamed, MP Ward, M Bates, CD Spillane, T Kelly, C Martin, ... Scientific Reports 13 (1), 3704, 2023 | 6 | 2023 |
| Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer RD Kalachand, C O’Riain, S Toomey, A Carr, KM Timms, S O’Toole, ... Obstetrics & gynecology science 63 (5), 643, 2020 | 6 | 2020 |
| Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression J Lazniewska, KL Li, IRD Johnson, A Sorvina, JM Logan, C Martini, ... Scientific reports 13 (1), 13489, 2023 | 2 | 2023 |
| Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapy TE Kelly, CL Spillane, MP Ward, K Hokamp, Y Huang, P Tewari, ... Frontiers in Cell and Developmental Biology 11, 2023 | 1 | 2023 |
